Take the steps now
to secure your future
LYNCHNOW® is a cost-effective, comprehensive screening that rapidly detects mutations that causes Lynch syndrome.
LYNCHNOW® is a comprehensive germline screening tool to test for Lynch syndrome and other hereditary cancer disorders in patients with colorectal cancer. This test is designed for colorectal cancer patients with a positive family history of hereditary cancers or a suspicion of Lynch syndrome (e.g. MSI-high or mismatch repair deficiency (dMMR)). We offer two iterations of the test: LYNCHNOW® Basic, which screens the Lynch Syndrome genes (MLH1, MSH2, MHS6, PMS2, EPCAM), and LYNCHNOW® Extended, a comprehensive 31-gene panel that identifies alterations in genes associated with Lynch syndrome and other hereditary disorders related to increased risk for colorectal cancer. Reflex options are available. Both versions of the assay utilize next-generation sequencing and detect single- and multi-nucleotide substitutions and small insertions and deletions in coding regions and exon-intron junctions, as well as large genomic rearrangements of the target genes, providing >1500X average coverage at the targeted genomic regions of the tested genes.
LYNCHNOW® delivers timely and cost-efficient results.
The protocol, which is largely accepted throughout the medical field, consists of first screening for DNA mismatch repair (MMR) proteins MLH1, MSH2, MSH6, and PMS2 by way of immunohistochemistry.

This process gives results in 3-5 days and allows the clinician to make a rapid decision on the next step.
Most hereditary cancers
This COMPREHENSIVE GERMLINE PANEL analyzes 88 clinically-relevant genes that are associated with genetic disorders, including most hereditary cancers.
Learn more
Prostate cancer
PROSTATENOW™ is a comprehensive germline test for people with prostate cancer. This test can be used to predict prognosis among men with localized prostate cancer, predict therapeutic responses for advanced patients, and predict cancer risk among unaffected men.
Learn more
Breast cancer
There is an increased likelihood of a BRCA1 or BRCA2 mutation in patients with certain personal and family history characteristics and various clinical criteria. BRCANOW® is a Next-Gen Sequencing (NGS)-based assay using a state-of-the-art platform to detect whether or not a mutation is present.
Learn more
We're here to guide you through the process.
Part of LYNCHNOW® includes genetic counseling to walk you through our process and test results, along with any lifestyle or treatment alternatives depending on your results.
Get in touch